Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: A randomized, open-label, single-dose, crossover study

Clinical Drug Investigation

Volumn 29, Issue 10, 2009, Pages 647-654

  Vasisht, Niraj ^a   Gever, Larry N ^b   Tagarro, Ignacio ^c   Finn, Andrew L ^a  

^a BioDelivery Sciences International Inc   (United States)

^b Meda Pharmaceuticals Inc   (United States)

^c Meda Pharmaceuticals   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; FENTANYL CITRATE; NALTREXONE; ONSOLIS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; FILM; HUMAN; INTERMETHOD COMPARISON; LOZENGE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PH; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADHESIVES; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; CALIBRATION; CHEEK; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FENTANYL; HUMANS; MALE; MOUTH MUCOSA; REFERENCE STANDARDS; YOUNG ADULT;

EID: 69549101611     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11315300-000000000-00000     Document Type: Article

References (25)

1. Data on file, BioDelivery Sciences International, Inc., Raleigh (NC), 2005
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain 1990 Jun; 41: 273-281
3. McCarberg BH. The treatment of breakthrough pain. Pain Med 2007 Jan-Feb; 8 (S1): S8-13
4. Actiq® package insert. Salt Lake City (UT): Cephalon Inc., 2007
5. Fentora® package insert. Salt Lake City (UT): Cephalon Inc., 2007
6. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991 Aug; 75 (2): 223-229
7. Chandler S. Oral transmucosal fentanyl citrate: a new treatment for breakthrough pain. Am J Hosp Palliat Care 1999 Mar-Apr; 16 (2): 489-491
8. Gordon D, Schroeder M. Oral transmucosal fentanyl citrate-OTFC (ACTIQ) #103. J Palliat Med 2008 May; 11 (4): 633-634
9. Mystakidou K, Katsouda E, Parpa E, et al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. J Opioid Manag 2005 Mar-Apr; 1 (1): 36-40
10. Darwish M, Kirby M, Robertson Jr P, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet 2006; 45 (8): 843-850 (Pubitemid 44182277)
11. Streisand JB, Zhang J, Niu S, et al. Buccal absorption of fentanyl is pH-dependent in dogs. Anesthesiology 1995 Mar; 82 (3): 759-764
12. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 2006; 4: 1-5
13. Metropolitan height and weight tables. New York (NY): Metropolitan Life Insurance Company, 1999
14. Food and Drug Administration, Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations. 2003 Mar [online]. Available from URL: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf [Accessed 2009 Aug 1]
15. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: part I. Assessment. P&T 2005 May; 30 (5): 296-301
16. Payne R. Recognition and diagnosis of breakthrough pain. Pain Med 2007 Jan-Feb; 8 Suppl. 1: S3-7 (Pubitemid 46128735)
17. Davies AN. Cancer-related breakthrough pain. Br J Hosp Med (Lond) 2006 Aug; 67 (8): 414-416
18. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002 Feb 1; 94 (3): 832-839
19. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blind, placebo-controlled trial for the treatment of breakthrough pain in cancer subjects. J Natl Cancer Inst 1998 Apr; 90 (8): 611-616 (Pubitemid 28204805)
20. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999 Feb; 79 (2-3): 303-312
21. Hanks GW, Nugent M, Higgs CM, et al. OTFC Multicentre Study Group. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 2004 Dec; 18 (8): 698-704
22. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006 Nov-Dec; 22 (9): 805-811 (Pubitemid 44627444)
23. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007 Jul-Aug; 5 (7): 327-334 (Pubitemid 350055013)
24. Darwish M, Kirby M, Robertson Jr P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007 Mar; 47 (3): 343-350 (Pubitemid 46294716)
25. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001 Mar; 91: 123-130